Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.50 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.48 |
| ▸ | CALCA | P06881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134420 | 1.00 | CALCRL (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL4559699 | 0.87 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL13050655 | 0.87 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL1198319 | 0.87 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL13036911 | 0.87 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| SCHEMBL3066255 | 0.87 | CALCRL (0.60) | CALCRLRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL3058435 | 0.86 | CALCRL (0.59) | CALCRLRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL4663029 | 0.86 | CALCRL (0.59) | CALCRLRAMP1CALCA | |
| SCHEMBL1198278 | 0.85 | CALCRL (0.46) | CALCRL | |
| SCHEMBL14363438 | 0.84 | CALCRL (0.57) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | claimed |
| EP-1664090-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050085425-A1 | Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2005-04-21 | — | — | US | claimed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-8993588-B2 | Carboxamide heterocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993588-B2 | Carboxamide heterocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2039694-B1 | CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2039694-B1 | CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-1799672-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1799672-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7893052-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2011-02-22 | — | — | US | disclosed |
| US-7893052-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2011-02-22 | — | — | US | disclosed |
| EP-1664090-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1638969-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050256098-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2005-11-17 | — | — | US | disclosed |
| US-6953790-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050085425-A1 | Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2005-04-21 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040229861-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004092166-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229861-A1 | CGRP receptor antagonists | CCKBR, CCKAR, CALCRL | CALCRL 3/4885RAMP1 191/4885CALCA 21/4885 |
| US-20050085425-A1 | Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | PRSS1, TMPRSS11D, TMPRSS2 | CALCRL 1793/4885RAMP1 484/4885CALCA 1292/4885 |
| US-20050256098-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885RAMP1 187/4885CALCA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.